Lautenschlaeger T, George A, Klimowicz AC, Efstathiou JA, Wu CL, Sandler H, Shipley WU, Tester WJ, Hagan MP, Magliocco AM, Chakravarti ABladder Preservation Therapy for Muscle-Invading Bladder Cancers on Radiation Therapy Oncology Group Trials 8802, 8903, 9506, and 9706: Vascular Endothelial Growth Factor B Overexpression Predicts for Increased Distant Metastasis and Shorter Survival.Oncologist in press 5/31/2013
Cottini F, Lautenschlaeger TPredictors of Biomarkers Guiding Targeted Therapeutic Strategies in Locally Advanced Lung Cancer.Cancer J 19(3) 263-271 5/1/2013
Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, Schultz CJ, Choucair A, Dolled-Filhart M, Christiansen J, Gustavson M, Molinaro A, Mischel P, Dicker AP, Bredel M, Mehta MRTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients.Int J Radiat Oncol Biol Phys 85(5) 1206-11 4/1/2013
Meng W, McElroy JP, Volinia S, Palatini J, Warner S, Ayers LW, Palanichamy K, Chakravarti A, Lautenschlaeger TComparison of MicroRNA Deep Sequencing of Matched Formalin-Fixed Paraffin-Embedded and Fresh Frozen Cancer Tissues.PLoS One 8(5) e64393 1/1/2013
Meng W, Huebner A, Shabsigh A, Chakravarti A, Lautenschlaeger TCombined RASSF1A and RASSF2A Promoter Methylation Analysis as Diagnostic Biomarker for Bladder Cancer.Mol Biol Int 2012 701814 1/1/2012